TY - JOUR
T1 - P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification
AU - Chan, Lauretta M.S.
AU - Cooper, Anne E.
AU - Dudley, Adam L.J.
AU - Ford, Dianne
AU - Hirst, Barry H.
N1 - Funding Information:
We thank Maxine Geggie for expert technical assistance. We also acknowledge the support and encouragement of Dr Keith Horspool (now of Pfizer Global R&D, Groton, CT) when at AstraZeneca in the early stage of this research. This work was supported by a BBSRC-CASE Studentship to LMSC and AstraZeneca R&D.
PY - 2004/8
Y1 - 2004/8
N2 - Human intestinal Caco-2 cell monolayers grown in the presence of 1α,25-dihydroxyvitamin D3 (1,25(OH 2D3) were used to test the hypothesis that drugs which interact with the apical efflux pump P-glycoprotein (Pgp) may enhance CYP3A4-mediated disappearance of substrates. 6β -Hydroxytestosterone production, a marker of CYP3A4 activity, was approximately 3- and 7-fold greater in 1,25(OH 2D3-treated cells compared to untreated cells when incubated with 50 and 500 μM testosterone, respectively, and was unaffected by the addition of digoxin to reduce Pgp activity. In the presence of digoxin, secretory transport of vinblastine and erythromycin, substrates for both Pgp and cytochrome P450 3A4 (CYP3A4), was significantly reduced, whereas absorptive transport was unaffected. In contrast, no directional transport of testosterone, a substrate for CYP3A4 only, was observed, either in the presence or absence of digoxin. Over 2 h, disappearance of erythromycin and vinblastine from the incubation medium was significantly greater from the basolateral than from the apical compartments. In the presence of digoxin, disappearance of both compounds from the basolateral, but not from the apical compartments, was significantly reduced. In contrast, disappearance of testosterone was unaffected by the addition of digoxin, demonstrating that the effect of digoxin on erythromycin and vinblastine disappearance was via inhibition of Pgp function, rather than on CYP3A4 activity. Thus, evidence is provided for Pgp/CYP3A4 co-substrates, Pgp potentiates CYP3A4-mediated drug disappearance during intestinal secretory detoxification.
AB - Human intestinal Caco-2 cell monolayers grown in the presence of 1α,25-dihydroxyvitamin D3 (1,25(OH 2D3) were used to test the hypothesis that drugs which interact with the apical efflux pump P-glycoprotein (Pgp) may enhance CYP3A4-mediated disappearance of substrates. 6β -Hydroxytestosterone production, a marker of CYP3A4 activity, was approximately 3- and 7-fold greater in 1,25(OH 2D3-treated cells compared to untreated cells when incubated with 50 and 500 μM testosterone, respectively, and was unaffected by the addition of digoxin to reduce Pgp activity. In the presence of digoxin, secretory transport of vinblastine and erythromycin, substrates for both Pgp and cytochrome P450 3A4 (CYP3A4), was significantly reduced, whereas absorptive transport was unaffected. In contrast, no directional transport of testosterone, a substrate for CYP3A4 only, was observed, either in the presence or absence of digoxin. Over 2 h, disappearance of erythromycin and vinblastine from the incubation medium was significantly greater from the basolateral than from the apical compartments. In the presence of digoxin, disappearance of both compounds from the basolateral, but not from the apical compartments, was significantly reduced. In contrast, disappearance of testosterone was unaffected by the addition of digoxin, demonstrating that the effect of digoxin on erythromycin and vinblastine disappearance was via inhibition of Pgp function, rather than on CYP3A4 activity. Thus, evidence is provided for Pgp/CYP3A4 co-substrates, Pgp potentiates CYP3A4-mediated drug disappearance during intestinal secretory detoxification.
KW - Absorption
KW - Caco-2
KW - CYP3A4
KW - Intestine
KW - P-glycoprotein
KW - Secretion
UR - http://www.scopus.com/inward/record.url?scp=9444272236&partnerID=8YFLogxK
U2 - 10.1080/10611860412331285224
DO - 10.1080/10611860412331285224
M3 - Article
C2 - 15621665
AN - SCOPUS:9444272236
SN - 1061-186X
VL - 12
SP - 405
EP - 413
JO - Journal of Drug Targeting
JF - Journal of Drug Targeting
IS - 7
ER -